Drug Profile
Eptotermin alfa - Ember Therapeutics
Alternative Names: 38A BMP-7 - Ember Therapeutics; Recombinant bone morphogenetic protein-7 - Ember Therapeutics; Recombinant osteogenetic protein-1 - Ember Therapeutics; rhBMP-7 - Ember Therapeutics; rhOP-1 - Ember TherapeuticsLatest Information Update: 10 Aug 2023
Price :
$50
*
At a glance
- Originator Stryker Corporation
- Developer Ember Therapeutics
- Class Bone morphogenetic proteins; Calcium regulators; Osteoporosis therapies; Recombinant proteins
- Mechanism of Action Apoptosis inhibitors; Collagen stimulants; Osteogenesis stimulants; Proteoglycan stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Osteoarthritis
- Discontinued Nephritis; Renal failure
Most Recent Events
- 10 Aug 2023 Discontinued - Preclinical for Nephritis in USA (Parenteral)
- 10 Aug 2023 Discontinued - Preclinical for Renal failure in USA (Parenteral)
- 28 Apr 2019 No recent reports of development identified for preclinical development in Nephritis in USA (Parenteral)